Singh Biotechnology CEO Dr Sunanda Singh tells Proactive the Florida-based 'virtual' biotech, who outsources all of its R&D to contract resource companies in the US, is in the late pre-clinical stage with its therapies to treat pancreatic and bone cancer. Singh says staying virtual allows the privately-held company to keep costs down. Singh is looking to raise more capital to push its therapies to Phase 1 studies.
0 Comments